Water-soluble inhibitor of Hsp90
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

17-DMAG

Item No. 11036

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
17-demethoxy-17-[[2-(dimethylamino)ethyl]amino]-geldanamycin
CAS Number
467214-20-6
Synonyms
  • Alvespimycin
  • KOS-1022
  • NSC 707545
Molecular Formula
C32H48N4O8
Formula Weight
616.8
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 20 mg/mlDMF:PBS(pH 7.2)(1:1): 0.5 mg/mlDMSO: 13 mg/mlEthanol: 2 mg/ml
λmax
220, 332, 529 nm
SMILES
O=C(C(NCCN(C)C)=C1C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(C)/[C@@H]2OC(N)=O)C=C(NC(/C(C)=C/C=C\[C@@H]2OC)=O)C1=O
InChi Code
InChI=1S/C32H48N4O8/c1-18-14-22-27(34-12-13-36(5)6)24(37)17-23(29(22)39)35-31(40)19(2)10-9-11-25(42-7)30(44-32(33)41)21(4)16-20(3)28(38)26(15-18)43-8/h9-11,16-18,20,25-26,28,30,34,38H,12-15H2,1-8H3,(H2,33,41)(H,35,40)/b11-9-,19-10+,21-16+/t18-,20+,25
InChi Key
KUFRQPKVAWMTJO-LMZWQJSESA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $41

    Add

    5 mg

    $128

    Add

    10 mg

    $215

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    17-DMAG is a water-soluble derivative of geldanamycin which potently inhibits Hsp90 (IC50 = 24 nM) and has excellent bioavailability and tissue distribution in animals.1 Like other Hsp90 inhibitors, 17-DMAG has diverse anti-tumor actions and has potential in treating certain types of cancer.2,3,4,5,6 This compound also suppresses inflammation by interfering with signaling through the NF-κB pathway.7,8 17-DMAG also ameliorates high fat diet-induced renal failure in a mouse model of diabetes.9

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Egorin, M.J., Lagattuta, T.F., Hamburger, D.R., et al. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother. Pharmacol. 49, 7-19 (2002).

    2. Bull, E.E.A., Dote, H., Brady, K.J., et al. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin. Cancer Res. 10, 8077-8084 (2004).

    3. Taldone, T., Sun, W., and Chiosis, G. Discovery and development of heat shock protein 90 inhibitors. Bioorg. Med. Chem. 17(6), 2225-2235 (2009).

    4. Hackl, C., Lang, S.A., Moser, C., et al. Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition. BMC Cancer 10(668), 1-9 (2010).

    5. Ramanathan, R.K., Egorin, M.J., Erlichman, C., et al. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J. Clin. Oncol. 28(9), 1520-1526 (2010).

    6. Kobayashi, N., Toyooka, S., Soh, J., et al. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Lung Cancer 75, 161-166 (2012).

    7. Madrigal-Matute, J., López-Franco, O., Blanco-Colio, L.M., et al. Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis. Cardiovasc. Res. 86, 330-337 (2010).

    8. Shimp, S.K., III, Parson, C.D., Regna, N.L., et al. HSP90 inhibition by 17-DMAG reduces inflammation in J774 macrophages through suppression of Akt and nuclear factor-κB pathways. Inflamm. Res. 1-13 (2012).

    9. Zhang, H.M., Dang, H., Kamat, A., et al. Geldanamycin derivative ameliorates high fat diet-induced renal failure in diabetes. PLoS One 7(3), 1-9 (2012).